Antiplatelets for Cardiovascular Disease in Non-valvular AF with Rivaroxaban: A Subanalysis of the EXPAND Study
Rivaroxaban with APT did not reduce ischemic outcomes in patients with stable CAD or ischemic stroke; however, it did increase the risk of bleeding in patients with stable CAD or ischemic stroke.
Authors
- Hideki Origasa (ORCID: https://orcid.org/0000-0002-9618-7361)
- Wataru Shimizu (ORCID: https://orcid.org/0000-0001-9941-8973)
- Hiroaki Shimokawa (ORCID: https://orcid.org/0000-0001-7534-4826)
- Masahiro Kamouchi (ORCID: https://orcid.org/0000-0002-5348-8762)
- Shinichiro Uchiyama (ORCID: https://orcid.org/0000-0002-6280-8190)
- Takanori Ikeda (ORCID: https://orcid.org/0000-0003-0096-438X)
- Takeshi Yamashita (ORCID: https://orcid.org/0000-0002-2544-8464)
- Takanari Kitazono (ORCID: https://orcid.org/0000-0002-9006-5937)
- Hirotsugu Atarashi (ORCID: https://orcid.org/0000-0001-8181-9154)
- Koji Fukuda (ORCID: https://orcid.org/0000-0001-7209-8420)
- Koichi Kaikita (ORCID: https://orcid.org/0000-0003-2962-8056)
- Hiroshi Inoue (ORCID: https://orcid.org/0000-0002-0775-8936)
Institutions
- University of Miyazaki (JP)
- Toho University (JP)
- Kyushu University (JP)
- Tohoku University (JP)
- Cardiovascular Institute Hospital (JP)
- The Institute of Statistical Mathematics (JP)
- Kitamurayama Hospital (JP)
- Sanno Medical Center (JP)
- International University of Health and Welfare (JP)
- Nippon Medical School (JP)
- Kumamoto University (JP)
Publication Details
- Journal
- Journal of Atherosclerosis and Thrombosis
- Published
- 2024-09-27
- DOI
- https://doi.org/10.5551/jat.64681
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bayer Yakuhin